Literature DB >> 15635580

Determinants of survival in parotid gland carcinoma: a population-based study.

Neil Bhattacharyya1, Marvin P Fried.   

Abstract

PURPOSE: To determine survival and factors influencing survival for parotid gland cancer.
METHODS: Cases of parotid gland malignancy were extracted from the SEER database for 1988 to 1998. Kaplan-Meier survival analysis was conducted for the most common tumor histologies. Cox proportional hazards modeling was conducted to determine the influence of age, gender, histopathology, grade, size, regional modal status, extraglandular extension, and radiation therapy on survival. Subset analysis was conducted for mucoepidermoid carcinoma according to grade.
RESULTS: Nine hundred three patients were identified with a mean age of 59.2 years. Mean follow-up was 51.8 months. Mean 5-year and 10-year actuarial survivals for the entire cohort were 87.8 months, 66.6% and 49.7%, respectively. Mean tumor size at diagnosis was 2.7 cm; 38.0% of patients had extraglandular extension of the tumor, 26.8% of patients had positive nodal disease, and 59.4% of patients received radiation therapy. Tumor histology did predict survival, with squamous cell carcinoma and acinar cell carcinoma exhibiting the poorest and best survivals, respectively. Stratified Cox proportional hazards modeling revealed that increasing age, tumor size, grade, extraglandular extension, and nodal positivity significantly negatively influenced survival (all P<or=.001); radiation therapy conferred a survival benefit (P=.090), whereas gender did not significantly affect survival. Increasing tumor grade, nodal disease, and extraglandular extension carried particularly high hazards ratios.
CONCLUSIONS: Survival in parotid gland malignancy is influenced by multiple factors. Patients with multiple poor prognostic features such as extraglandular extension, aggressive tumor histologies, and nodal disease will exhibit poorer survivals and may be candidates for more aggressive treatment protocols.

Entities:  

Mesh:

Year:  2005        PMID: 15635580     DOI: 10.1016/j.amjoto.2004.06.017

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  16 in total

1.  Occurrence of lymph node metastasis in early-stage parotid gland cancer.

Authors:  Markus Stenner; Christoph Molls; Jan C Luers; Dirk Beutner; Jens P Klussmann; Karl-Bernd Huettenbrink
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-06-14       Impact factor: 2.503

2.  Outcome and management of rare high-grade "salivary" adenocarcinoma: the important role of adjuvant (chemo)radiotherapy.

Authors:  Claudia Scherl; Marlen Haderlein; Abbas Agaimy; Konstantinos Mantsopoulos; Michael Koch; Maximilian Traxdorf; Rainer Fietkau; Philipp Grundtner; Heinrich Iro
Journal:  Strahlenther Onkol       Date:  2019-07-26       Impact factor: 3.621

3.  Postoperative [¹²⁵I] seed brachytherapy in the treatment of acinic cell carcinoma of the parotid gland: with associated risk factors.

Authors:  Ming-Hui Mao; Jian-Guo Zhang; Jie Zhang; Lei Zheng; Shu-Ming Liu; Ming-Wei Huang; Yan Shi
Journal:  Strahlenther Onkol       Date:  2014-04-29       Impact factor: 3.621

4.  Role of Intraparotid and Neck Lymph Node Metastasis in Primary Parotid Cancer Surgery: A Population-Based Analysis.

Authors:  Mussab Kouka; Benjamin Koehler; Jens Buentzel; Holger Kaftan; Daniel Boeger; Andreas H Mueller; Andrea Wittig; Stefan Schultze-Mosgau; Thomas Ernst; Peter Schlattmann; Orlando Guntinas-Lichius
Journal:  Cancers (Basel)       Date:  2022-06-07       Impact factor: 6.575

Review 5.  Salivary gland carcinomas.

Authors:  Tobias Ettl; Stephan Schwarz-Furlan; Martin Gosau; Torsten E Reichert
Journal:  Oral Maxillofac Surg       Date:  2012-07-29

6.  Racial and Ethnic Disparities in Salivary Gland Cancer Survival.

Authors:  Joseph L Russell; Nai-Wei Chen; Shani J Ortiz; Travis P Schrank; Yong-Fang Kuo; Vicente A Resto
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-06       Impact factor: 6.223

7.  [Prognostic value of immunohistochemistry in salivary gland cancer].

Authors:  T Ettl; S Schwarz; T Kühnel; P Stockmann; T E Reichert; O Driemel
Journal:  HNO       Date:  2008-02       Impact factor: 1.284

8.  Primary and non-primary parotid malignancies: comparison of treatment modalities and outcomes.

Authors:  Sylvain Morinière; Sophie Périé; Jean Lacau St Guily
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-05-30       Impact factor: 2.503

9.  Competing-risks nomograms for predicting cause-specific mortality in parotid-gland carcinoma: A population-based analysis.

Authors:  Fengshuo Xu; Xiaojie Feng; Fanfan Zhao; Qiao Huang; Didi Han; Chengzhuo Li; Shuai Zheng; Jun Lyu
Journal:  Cancer Med       Date:  2021-05-07       Impact factor: 4.452

10.  Gender and ploidy in cancer survival.

Authors:  Susanne Schulze; Iver Petersen
Journal:  Cell Oncol (Dordr)       Date:  2011-03-22       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.